NCT04401189 (CHRONO) is a clinical trial in Breast Cancer, sponsored by Aarhus University Hospital.

Who is sponsoring NCT04401189?

NCT04401189 is sponsored by Aarhus University Hospital.

What condition does NCT04401189 study?

NCT04401189 studies Breast Cancer, Fatigue, Cognitive Impairment, Sleep, Depression, Quality of Life, Stress, Psychological, Inflammation, Circadian Rhythm Disorders, Cancer-Related Syndrome.

Is NCT04401189 still recruiting?

NCT04401189 is currently completed. Last updated 28 June 2024.

Last reviewed 2024-06-28 · How we verify

NCT04401189: CHRONO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Circadian Rhythms in Cancer-Related Symptoms

Completed Last updated 28 June 2024

What this trial tests

trial in Breast Cancer in 124 participants. Completed in 30 June 2023.

Timeline

1 June 2020

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Aarhus University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	124
Start date	1 June 2020
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across Denmark

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Fatigue — all drugs for Fatigue →
Cognitive Impairment — all drugs for Cognitive Impairment →
Sleep — all drugs for Sleep →

Sponsor

Aarhus University Hospital

Who can join

18 and older, female only, with Breast Cancer or Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Emerging evidence indicates that circadian rhythms may be disrupted following cancer and its treatment, and that circadian rhythm disruption may be an underlying pathophysiological mechanism of cancer- and cancer treatment-related symptoms (CRS) such as fatigue, sleep disturbance, cognitive impairment, and depressed mood. Given the detrimental effect of CRS on cancer survivors' quality of life, and a pressing demand for effective interventions to treat CRS, there is a need for a comprehensive examination of circadian disruption related to cancer and its treatment, and its association with CRS. The study will prospectively examine circadian rhythms and a CRS composite score in recently diagnosed breast cancer patients from prior to surgery or chemotherapy to 12 months later. A matched healthy control group will serve as a comparison.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
Griñan-Lison C, Blaya-Cánovas JL, López-Tejada A, Ávalos-Moreno M, et al · · 2021 · cited 43× · PMID 33572626 · DOI 10.3390/antiox10020205
Integration of circadian rhythms and immunotherapy for enhanced precision in brain cancer treatment.
Quist M, van Os M, van Laake LW, Bovenschen N, et al · · 2024 · cited 11× · PMID 39413708 · DOI 10.1016/j.ebiom.2024.105395
Thirty-Sixth Annual Meeting of the Society for Light, Rhythms, and Circadian Health (SLRCH), 14-16 June, Boston, MA, USA.
Garbazza C. · · 2025 · PMID 41562649 · DOI 10.3390/clockssleep8010002
Circadian clocks and adaptive immune function: from mechanisms to therapeutic applications.
Szredzka A, Chwastowicz A, Pergoł J, Matryba P. · · 2025 · PMID 41415271 · DOI 10.3389/fimmu.2025.1697854

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Aarhus University Hospital trials

Trials by the same sponsor.

NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04401189 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
Last refreshed: 28 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401189.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing